You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

CLINICAL TRIALS PROFILE FOR DAUNORUBICIN CITRATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for daunorubicin citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00427414 ↗ Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma Terminated National Cancer Institute (NCI) Phase 1 2008-09-01 RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
NCT00427414 ↗ Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma Terminated The Emmes Company, LLC Phase 1 2008-09-01 RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
NCT00427414 ↗ Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma Terminated The EMMES Corporation Phase 1 2008-09-01 RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
NCT00427414 ↗ Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma Terminated AIDS Malignancy Consortium Phase 1 2008-09-01 RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
NCT00967057 ↗ Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed Children's Cancer and Leukaemia Group Phase 3 2002-10-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: This partially randomized phase III trial is studying how well combination chemotherapy works in treating young patients with relapsed or refractory acute lymphoblastic leukemia.
NCT03299452 ↗ Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor Unknown status Alphacait, LLC Phase 2 2017-01-01 This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.
NCT03299452 ↗ Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor Unknown status Haining Health-Coming Biotech Co., Ltd. Phase 2 2017-01-01 This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for daunorubicin citrate

Condition Name

Condition Name for daunorubicin citrate
Intervention Trials
Leukemia 1
Metastatic Cancer 1
Sarcoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for daunorubicin citrate
Intervention Trials
Sarcoma, Kaposi 1
Sarcoma 1
Neoplasm Metastasis 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for daunorubicin citrate

Trials by Country

Trials by Country for daunorubicin citrate
Location Trials
China 1
Brazil 1
Australia 1
United Kingdom 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for daunorubicin citrate
Location Trials
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for daunorubicin citrate

Clinical Trial Phase

Clinical Trial Phase for daunorubicin citrate
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for daunorubicin citrate
Clinical Trial Phase Trials
Completed 1
Terminated 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for daunorubicin citrate

Sponsor Name

Sponsor Name for daunorubicin citrate
Sponsor Trials
National Cancer Institute (NCI) 1
The Emmes Company, LLC 1
The EMMES Corporation 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for daunorubicin citrate
Sponsor Trials
Other 4
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.